Premixed insulins are an important tool for glycemic control in persons with diabetes. Equally important in diabetes care is the selection of the most appropriate insulin regimen for a particular individual at a specific time. Currently, the choice of insulin regimens for initiation or intensification of therapy is a subjective decision. In this article, we share insights, which will help in rational and objective selection of premixed formulations for initiation and intensification of insulin therapy. The glycemic status and its variations in a person help to identify the most appropriate insulin regimen and formulation for him or her. The evolution of objective glucometric indices has enabled better glycemic monitoring of individuals with...
Q1Artículo original183-200Objective: We produced, through a systematic review of quantitative and qu...
Background: Few studies evaluate patients' perspectives when a new drug is introduced to treat chron...
OBJECTIVE: While sodium-glucose cotransporter inhibitor (SGLTi) therapy has been evaluated in type 1...
Diabetes is a highly prevalent chronic disease worldwide. It was observed inKing Abdul-Aziz Cardiac ...
Diabetes is a highly prevalent chronic disease worldwide. It was observed inKing Abdul-Aziz Cardiac ...
Brazil is expected to have 19.6 million patients with diabetes by the year 2030. A key concept in th...
Background: To compare the patient-led titration (intervention group) versus physician-led titration...
Diabetes is associated with microvascular andmacrovascular complications leading tosignificant morbi...
Research Objective: To explore which insulin formulations and which regime is the most effective at ...
Full copyright for enhanced digital features is owned by the authors. Article full text The fu...
Item does not contain fulltextBACKGROUND: Optimal glucose-lowering therapy in type 2 diabetes mellit...
achieving best practice It is estimated that 39 % of diabetic patients worldwide that use insulin th...
Aim: To assess diabetes treatment preferences with a focus on patient barriers to insulin treatment....
Insulin initiation, which was traditionally the province of specialists, is increasingly undertaken ...
The goals of Type 2 diabetes treatment are to eliminate the hyperglycemia resulting from insulin ins...
Q1Artículo original183-200Objective: We produced, through a systematic review of quantitative and qu...
Background: Few studies evaluate patients' perspectives when a new drug is introduced to treat chron...
OBJECTIVE: While sodium-glucose cotransporter inhibitor (SGLTi) therapy has been evaluated in type 1...
Diabetes is a highly prevalent chronic disease worldwide. It was observed inKing Abdul-Aziz Cardiac ...
Diabetes is a highly prevalent chronic disease worldwide. It was observed inKing Abdul-Aziz Cardiac ...
Brazil is expected to have 19.6 million patients with diabetes by the year 2030. A key concept in th...
Background: To compare the patient-led titration (intervention group) versus physician-led titration...
Diabetes is associated with microvascular andmacrovascular complications leading tosignificant morbi...
Research Objective: To explore which insulin formulations and which regime is the most effective at ...
Full copyright for enhanced digital features is owned by the authors. Article full text The fu...
Item does not contain fulltextBACKGROUND: Optimal glucose-lowering therapy in type 2 diabetes mellit...
achieving best practice It is estimated that 39 % of diabetic patients worldwide that use insulin th...
Aim: To assess diabetes treatment preferences with a focus on patient barriers to insulin treatment....
Insulin initiation, which was traditionally the province of specialists, is increasingly undertaken ...
The goals of Type 2 diabetes treatment are to eliminate the hyperglycemia resulting from insulin ins...
Q1Artículo original183-200Objective: We produced, through a systematic review of quantitative and qu...
Background: Few studies evaluate patients' perspectives when a new drug is introduced to treat chron...
OBJECTIVE: While sodium-glucose cotransporter inhibitor (SGLTi) therapy has been evaluated in type 1...